HypErthermia as an Additional Treatment for the Biology and Experience of Depression
| 适应症 | Major Depressive Disorder |
|---|---|
| 分期 | 不适用 |
| 申办方 | University of California, San Francisco |
| 状态 | 已完成 |
| 受试者人数 | 16 人 |
| 干预（药物） | Cognitive Behavioral Therapy (CBT), Whole-Body Hyperthermia (WBH) |
| 开始日期 | 2021年10月11日 |
| 完成日期 | 2023年3月1日 |
| 结果公布日 | 2024年6月12日 |
摘要
This single-arm feasibility trial administered up to 8 weekly (early phase) or 4 bi-weekly (later phase) whole-body hyperthermia (WBH) sessions and 8 weekly cognitive behavioral therapy (CBT) sessions to adults aged 18 years or older with major depressive disorder (MDD).
Average Number of Planned WBH Sessions Completed
| Cognitive Behavioral Therapy (CBT) and 8 Sessions Whole-Body Hyperthermia (WBH) | 7.83 ± 0.41 Count of WBH Sessions |
|---|---|
| Cognitive Behavioral Therapy (CBT) and 4 Sessions Whole-Body Hyperthermia (WBH) | 3.20 ± 1.40 Count of WBH Sessions |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- CBT+ for Depression — University of Wisconsin, Madison
- Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neu — Stanford University
- Severe Asthma, MepolizumaB and Affect: SAMBA Study — University Hospital Southampton NHS Foundation Trust
- Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for — Levomecor Inc.
- A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major De — Levomecor Inc.
- Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders — Massachusetts General Hospital